{ "items": [ "\n\n
\n \n 6 July 2016\n \n
\n\n \n \n \n\n \n \n \nProfessor Dave Stuart's group have studied the structure of the Ebola virus and the effect of two drugs, toremifene and ibruprofen on the virus. The study was the first to solve the unligated structure of the Ebola virus glycoprotein and the results were published in Nature.
\n \n\n\n \n 6 July 2016\n \n
\n\n \n \n \n\n \n \n \nLast week, the Village Drama Against Malaria initiative held its first performance in O Treng (Reed River), a remote rural Cambodian village that suffers from malaria. Over 200 people, more than half the village, attended the performance, which featured five village singers and primary school kids dressed as mosquitoes singing a song about malaria.
\n \n\n\n \n 28 June 2016\n \n
\n\n \n \n \n\n \n \n \nProfessor Chris Conlon, Interim Head of Department, attended the First Beijing International Conference on Precision Medicine and Cancer Treatment where he gave a talk on Medical Education in the 21st Century. He highlighted the importance of combining theoretical knowledge and clinical experience and discusssed the impact of sequencing the human genome to medicine. He also discussed some of the problems existing in medical education in different countries.
\n \n\n\n \n 28 June 2016\n \n
\n\n \n \n \n\n \n \n \nMucosal Associated Invariant T-cells (MAIT cells) were first identified in 1993 but largely ignored until recently. Australian researchers recently found that they had an important role in fighting bacterial infections. Now, the Oxford team, led by Professor Paul Klenerman, say that they also fight viruses. Their results are in the journal Nature Communications.
\n \n\n\n \n 28 June 2016\n \n
\n\n \n \n \n\n \n \n \nAn international team of researchers led by Professor Dominic Kwiatkowski has discovered that the malaria parasite Plasmodium vivax is evolving rapidly to adapt to conditions in different geographical locations, in particular to defend itself against widely-used antimalarial drugs.
\n \n\n\n \n 17 June 2016\n \n
\n\n \n \n \n\n \n \n \nAn NDM supported talk at this year\u2019s Cheltenham Science Festival, \u201cEmerging Diseases: From Ebola to Zika\u201d featured prominent epidemiologists and academics from the London School of Hygiene and Tropical Medicine and the Centre for Tropical Medicine and Global Health, University of Oxford.
\n \n\n\n \n 17 June 2016\n \n
\n\n \n \n \n\n \n \n \nThe Nuffield Department of Medicine was a Festival Partner of Cheltenham Science Festival again in 2016 and we supported six days of hands-on demonstration activities in the Discover Zone. Over the course of the festival several thousand people dropped by the stall and tried their hand at one of the many interactive activities on offer. The feedback from everyone we polled was overwhelmingly positive. Thank you to all the fantastic volunteers who made this event possible.
\n \n\n\n \n 31 May 2016\n \n
\n\n \n \n \n\n \n \n \nA global network of researchers, coordinated from the Wellcome Trust Centre for Human Genetics in Oxford, carried out a genome-wide association study to identify which genes might be associated with an increased likelihood of developing bacteraemia. Bacteraemia is a bacterial infection of the bloodstream and a major cause of illness and death in sub-Saharan Africa but little is known about whether human genetics play a part.
\n \n\n\n \n 18 May 2016\n \n
\n\n \n \n \n\n \n \n \nProfessor Helen McShane and her team have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis. The researchers have identified new biomarkers which have shown for the first time why immunity from the BCG vaccine is so variable. The biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
\n \n\n\n \n 18 May 2016\n \n
\n\n \n \n \n\n \n \n \nResults of the trial of the experimental anti-Ebola drug TKM-130803 have been published today. Using a novel approach designed to get rapid indications of a drug's effectiveness, the trial showed that at the dose given the drug did not improve survival compared to historic controls.
\n \n\n